Wells Fargo & Company Cardiff Oncology, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 7,825 shares of CRDF stock, worth $17,606. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,825
Previous 7,820
0.06%
Holding current value
$17,606
Previous $11,000
272.73%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CRDF
# of Institutions
86Shares Held
9.45MCall Options Held
798KPut Options Held
39.2K-
Vanguard Group Inc Valley Forge, PA1.92MShares$4.32 Million0.0% of portfolio
-
Assenagon Asset Management S.A.1.22MShares$2.74 Million0.01% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$2.09 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$1.54 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$1.52 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $97.5M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...